Abstract
Irbesartan did not reduce cardiovascular events in patients with atrial fibrillation. (Funded by Bristol-Myers Squibb and Sanofi-Aventis; ClinicalTrials.gov number, NCT00249795.).
Original language | English |
---|---|
Pages (from-to) | 928-938 |
Number of pages | 11 |
Journal | New England Journal of Medicine |
Volume | 364 |
Issue number | 10 |
DOIs | |
Publication status | Published - 2011 |